



**Universiteit
Leiden**
The Netherlands

Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification

Kavousi, M.; Bos, M.M.; Barnes, H.J.; Cardenas, C.L.L.; Wong, D.R.; Lu, H.J.; ... ; Miller, C.L.

Citation

Kavousi, M., Bos, M. M., Barnes, H. J., Cardenas, C. L. L., Wong, D. R., Lu, H. J., ... Miller, C. L. (2023). Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification. *Nature Genetics*, 55, 1651-1664.
doi:10.1038/s41588-023-01518-4

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3764322>

Note: To cite this publication please use the final published version (if applicable).

Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification

Received: 20 November 2022

Accepted: 29 August 2023

Published online: 28 September 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Coronary artery calcification (CAC), a measure of subclinical atherosclerosis, predicts future symptomatic coronary artery disease (CAD). Identifying genetic risk factors for CAC may point to new therapeutic avenues for prevention. Currently, there are only four known risk loci for CAC identified from genome-wide association studies (GWAS) in the general population. Here we conducted the largest multi-ancestry GWAS meta-analysis of CAC to date, which comprised 26,909 individuals of European ancestry and 8,867 individuals of African ancestry. We identified 11 independent risk loci, of which eight were new for CAC and five had not been reported for CAD. These new CAC loci are related to bone mineralization, phosphate catabolism and hormone metabolic pathways. Several new loci harbor candidate causal genes supported by multiple lines of functional evidence and are regulators of smooth muscle cell-mediated calcification *ex vivo* and *in vitro*. Together, these findings help refine the genetic architecture of CAC and extend our understanding of the biological and potential druggable pathways underlying CAC.

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed and developing countries^{1,2}. Atherosclerosis is the primary etiology of CAD, involving chronic lesion progression and luminal narrowing of arteries³. Subclinical coronary atherosclerosis is associated with an increased risk of developing future clinical CAD in males and females and across populations, which is independent of traditional risk factors^{4–6}. Subclinical coronary atherosclerosis can be detected noninvasively as coronary artery calcification (CAC) by cardiac computed tomography. Detectable CAC has a sensitivity of 97% and a specificity of 72.4% for detection of at least 50% stenosis after adjusting for verification bias⁷. Current clinical guidelines recommend assessment of CAC as an option to clarify atherosclerotic cardiovascular disease (CVD) risk and to improve management decisions for those at borderline or intermediate atherosclerotic CVD risk⁸.

The degree of CAC varies widely, with microcalcification or spotty, fragmented calcification being associated with unstable plaque and advanced sheet-like calcification being associated with stable plaque^{9,10}. Several studies have demonstrated the key role of smooth muscle cells

(SMCs) in vascular calcification as they transition from a contractile to osteochondrogenic phenotype and release matrix vesicles and apoptotic bodies in the necrotic core^{11,12}. Notably, increased CAC is also associated with increased risk of other age-related diseases, such as stroke, dementia, cancer, chronic kidney disease, chronic obstructive pulmonary disease and hip fractures in the general population^{13–15}.

Based on family data, the estimated heritability for CAC is 30–40%^{16,17}. Prior genome-wide association studies (GWAS) from general population cohorts have identified noncoding single-nucleotide polymorphisms (SNPs) at 9p21 (*CDKN2B-AS1*) and 6p24 (*PHACTR1*) as well as a protein-coding variant in *APOB* associated with a greater extent of CAC in individuals of European ancestry^{18–20}. Another protein-coding variant in *APOE* was associated with CAC in individuals of both European and African ancestries¹⁸. These four loci identified for CAC are also associated with a greater risk for CAD²¹.

We carried out the largest CAC GWAS meta-analysis to date by analyzing 1000 Genomes Phase 3-imputed genotype data from 35,776 individuals of European and African ancestries through a collaboration

✉ e-mail: m.kavousi@erasmusmc.nl; clintm@virginia.edu




Fig. 1 | Study summary. Schematic of study design and meta-analysis for CAC in European and African ancestry participants (1 and 2), main results identifying 16 lead SNPs in 11 loci (3), and post-GWAS analyses involving variant annotation and gene mapping in silico, functional validation in vitro and druggability analysis (4). Figure created in BioRender.

between the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium²² and other collaborating cohorts. We then performed a series of in silico functional genomic analyses to (1) gain mechanistic and biological insights into how the identified genetic loci impact CAC quantity, (2) prioritize the most clinically relevant CAC loci and (3) identify potential druggable targets for CAC. Finally, our ex vivo and in vitro experimental studies support our main genetic findings and provide motivation for future mechanistic and translational studies.

Results

Multi-ancestry CAC genome-wide association meta-analysis

We performed a GWAS meta-analysis of CAC quantity expressed in Agatston scores²³ from 35,776 individuals of European and African ancestries across cohorts in the CHARGE Consortium and collaborating cohorts (Fig. 1 and Supplementary Table 1). We identified 16 lead significant SNPs (Table 1) through linkage disequilibrium (LD)-based clumping (at $r^2 < 0.1$ using the 1000G Phase 3 reference) resulting in 11 independent genomic risk loci (Supplementary Figs. 1–3 and Supplementary Table 2; Methods). Among these 11 loci, 8 were new for CAC at genome-wide significance threshold (Table 1); associations at *PHACTR1* (6p24.1), *CDKN2B-AS1/CDKN2B* (9p21.3) and *APOE* (19q13.32) replicated known findings in multicohort GWAS^{18,19}. We annotated the lead SNP in the 11 loci and identified two missense lead SNPs in *IGFBP3* and *APOE*, while the remaining SNPs were annotated as noncoding (Table 1).

The specific *APOB* association reported earlier¹⁸ was not replicated here, most likely because the Old Order Amish were not included in this study and they have the highest frequency of a rare coding variant (R3500G) associated with CAC²⁴.

We also performed sex-stratified GWAS and SNP–sex interaction tests (Methods) for the 11 lead SNPs using a subset of the cohorts with available data (Supplementary Table 3). Despite the lower sample sizes, we found genome-wide significant associations with CAC at *PHACTR1* for both males and females and at *CDKN2B-AS1/CDKN2B* for males. We found two significant SNP–sex interaction signals ($P < 4.53 \times 10^{-3}$) at the AT-rich interaction domain 5B (*ARID5B*) and *CDKN2B-AS1/CDKN2B* loci, with a stronger allelic effect in males compared to females despite similar allele frequencies.

Conditional and credible set analysis for CAC loci

We performed conditional analyses on the summary statistics from the European ancestry cohorts²⁵, which identified three additional conditionally independent significant SNPs, not identified through LD-clumping, at *CDKN2B-AS1/CDKN2B* and *CXCL12* loci (Supplementary Table 4; Methods). We then performed credible set analyses to refine the association signals²⁶. As expected, the 95% credible set reduced the number of candidate causal variants at most loci, notably including only a single candidate variant at *PHACTR1*, *FGF23* and *APOE* loci (Supplementary Table 5). By leveraging ancestry-stratified analyses, the African ancestry meta-analyzed results reduced the

Table 1 | New and known independent lead SNPs associated with CAC

rsID	Chr	Pos (hg19)	Effect/ other allele	EAf	Effect	s.e.	P_{meta}	I^2	P_{het}	Nearest gene(s) ^a	Annotation
New loci for CAC quantity											
rs3844006	6	132,095,002	T/C	0.221	-0.114	0.020	7.56×10^{-9}	0.5	0.453	miR-548h-5 (dist.: 18,309 bp), ENPP3 (dist.: 26,449 bp), ENPP1 (dist.: 34,154 bp)	Intergenic
rs2854746	7	45,960,645	C/G	0.414	0.110	0.018	5.33×10^{-10}	0	0.760	IGFBP3	Missense
rs10899970	10	44,515,716	A/G	0.474	0.095	0.017	2.91×10^{-8}	0	0.940	AL512640.1 (dist.: 14,271 bp), CXCL12 (dist.: 366,225 bp)	Intergenic
rs9633535	10	63,836,088	T/C	0.371	0.098	0.018	2.57×10^{-8}	4	0.407	ARID5B	Intronic
rs10762577	10	75,917,431	A/G	0.258	-0.107	0.019	4.09×10^{-8}	0	0.683	ADK	Intronic
rs11063120	12	4,486,618	A/G	0.303	-0.133	0.022	2.78×10^{-9}	56	0.001	FGF23	Intronic
rs9515203	13	111,049,623	T/C	0.732	0.123	0.022	1.43×10^{-8}	0	0.744	COL4A1 (dist.: 90,119 bp), COL4A2 (dist.: -91,464 bp)	Intronic
rs7182103	15	79,123,946	T/G	0.575	0.112	0.017	1.62×10^{-11}	4.1	0.405	ADAMTS7 (dist.: -20,140 bp), MORF4L1 (dist.: 21,117 bp)	Intronic
Known loci for CAC quantity											
rs10456561	6	12,887,465	A/G	0.036	0.375	0.069	4.76×10^{-8}	14.7	0.292	PHACTR1	Intronic
rs35355695	6	12,891,103	T/G	0.256	-0.115	0.020	4.87×10^{-9}	5.2	0.390	PHACTR1	Intronic
rs9349379	6	12,903,957	A/G	0.623	-0.218	0.020	6.11×10^{-29}	18	0.234	PHACTR1	Intronic
rs10811650	9	22,067,593	A/G	0.619	-0.195	0.018	2.15×10^{-27}	53.2	0.003	CDKN2B-AS1	ncRNA intronic
rs72652478	9	22,102,043	C/G	0.957	-0.479	0.081	3.82×10^{-9}	0	0.983	CDKN2B-AS1	ncRNA intronic
rs62555371	9	22,107,238	A/T	0.866	0.270	0.032	5.49×10^{-17}	20.9	0.190	CDKN2B-AS1	ncRNA intronic
rs4977575	9	22,124,744	C/G	0.455	-0.264	0.018	7.49×10^{-47}	45	0.012	CDKN2B-AS1 (dist.: -3,651 bp), CDKN2B (dist.: 115,440 bp)	Intergenic
rs7412	19	45,412,079	T/C	0.090	-0.313	0.039	4.42×10^{-16}	0	0.657	APOE	Missense

Top lead SNPs in genomic risk loci associated with CAC quantity at a significance level of $P < 5 \times 10^{-8}$ for the combined ancestry meta-analysis (up to 35,776 individuals from 22 studies). SNP effect sizes (β) and two-sided P values (P_{meta}) were derived from weighted Z-scores in a fixed-effects model and central association P values determined from chi-square test statistics. rsID, rsID of the lead SNP. Lead SNP chromosome (Chr) and position (Pos) are provided in hg19/b37 and hg38. Effect/other allele indicates the effect and other (noneffect) allele. EAf, effect allele frequency. Effect, effect size. s.e., standard error of the effect. P_{meta} , P value of association of the lead SNP with CAC after multi-ancestry meta-analysis. I^2 , heterogeneity statistic indicating the variation between CAC quantity across the studies, expressed as a percent. P_{het} , P value of the heterogeneity test; $P > 0.05$ is indicative of study homogeneity for a given SNP. Nearest gene(s), nearest gene upstream or downstream and nearest protein-coding gene(s) to lead SNPs, with distance to canonical TSS for intergenic SNPs or intronic SNPs with equidistant protein-coding genes. Annotation, functional annotation of lead SNPs. SNP rs4977575 and rs10811650 reside 57,151 bp apart ($r^2 = 0.116$, $D' = 0.643$). SNP rs4977575 and rs62555371 reside 17,506 bp apart ($r^2 = 0.076$, $D' = 0.983$). SNP rs9349379 and rs35355695 reside 12,854 bp apart ($r^2 = 0.088$, $D' = 0.988$). SNP rs9349379 and rs10456561 reside 16,492 bp apart ($r^2 = 0.027$, $D' = 0.981$). ^aReported is either the gene that overlaps with the SNP or the nearest gene(s) upstream and downstream of the sentinel variant (separated by a comma).

credible set size for 8 of 11 loci, particularly for loci with broad association signals (for example, *CXCL12*; Supplementary Table 5 and Supplementary Fig. 3).

CAC loci to gene annotation

We identified 38 candidate genes using FUMA²⁷ through a combination of positional gene mapping, expression quantitative trait loci (eQTL) and chromatin interaction mapping (Methods; Supplementary Table 6). We identified another two candidate genes (*C9orf53* and *C6orf195*) through a genome-wide gene association analysis (MAGMA²⁸; Supplementary Table 7 and Supplementary Figs. 4 and 5). We also identified three candidate genes (*ENPP1*, *ENPP3* and *CXCL12* in Table 1) by annotating the nearest protein-coding genes that were not mapped through other methods (Methods). These 43 candidate causal CAC genes identified using locus-specific methods (Supplementary Fig. 5) were further annotated through a polygenic priority score (PoPS)²⁹ analysis (Supplementary Table 8). This provided support for several genes that were nonsignificant using MAGMA, emphasizing the need for orthogonal gene prioritization methods.

Prioritization of candidate causal CAC genes

To prioritize candidate causal CAC genes, we performed summary-based Mendelian randomization (SMR)³⁰ and colocalization³¹. The SMR–heterogeneity in dependent instruments (HEIDI) test determines whether the effect size on the GWAS trait is mediated by gene expression using eQTLs³⁰. By integrating the European-ancestry CAC meta-analysis summary statistics and cardiometabolic tissue *cis*-eQTLs from STARNET^{32,33}, we identified 11 and 18 gene expression–trait associations using eQTLs in atherosclerotic aortic root (AOR) and subclinical/nonatherosclerotic internal mammary artery (MAM) tissues, respectively (Fig. 2 and Supplementary Table 9). This supports that the effects of the CAC variants are likely mediated by gene expression differences. To provide additional functional fine-mapping evidence, we performed colocalization using coloc³¹, which revealed colocalization of CAC variants with *cis*-eQTLs in 22, 25 and 7 genes, in AOR, MAM and liver (LIV), respectively (Fig. 2 and Supplementary Table 10). We observed the strongest evidence of colocalization at known CAD loci *PHACTR1* and *ADAMTS7* in AOR, consistent with recent fine-mapping studies³⁴. As expected, we observed substantial overlap between prioritized genes associated




Fig. 2 | Prioritization of CAC causal genes using STARNET eQTLs. **a, b**, SMR to identify causal CAC genes using subclinical atherosclerotic MAM (**a**) and AOR (**b**) tissue *cis*-eQTLs in STARNET. Dashed black and red lines indicate SMR *P* value significance thresholds for tested CAC and CAD candidate genes, respectively. Teal green dots represent significant genes for both CAC and CAD, while blue dots represent those only significant for CAC. SMR *P* value determined by approximate chi-square test statistic for mediating effect of gene expression

on CAC or CAD. **c, d**, Coloc-based colocalization analysis of CAC and CAD candidate genes using STARNET MAM (**c**) and AOR (**d**) *cis*-eQTLs. Dashed black lines indicate high colocalization ($PP4 > 0.8$), and dashed red lines indicate low colocalization ($PP4 < 0.5$) thresholds. Teal green dots represent high colocalized genes ($PP4 > 0.8$) for both CAC and CAD, whereas blue dots represent those highly colocalized for CAC ($PP4 > 0.8$) but not CAD ($PP4 < 0.5$).

with CAC and CAD ($PP4 > 0.80$ for both traits). However, we also identified a subset of genes with strong evidence of colocalization with CAC ($PP4 > 0.80$) but not CAD ($PP4 < 0.50$), such as *IGFBP3*. Notably, *IGFBP3* was identified as a target gene using SMR in both AOR and MAM, suggesting a causal role in both early and advanced atherosclerosis.

To further resolve the regulatory mechanisms of GWAS variants^{35,36}, we performed epigenomic fine mapping of the combined European- and African-ancestry summary statistics using activity-by-contact³⁷ and enhancer–gene linking³⁸ methods. Using a suggestive threshold for CAC-associated variants ($P < 1 \times 10^{-5}$), we identified 42 and 54 variants (among 1,526 candidate variants) overlapping enhancer–promoter contacts for predicted target genes in human coronary artery smooth muscle cells (HCASMCs) and coronary artery, respectively (Supplementary Table 11 and Supplementary Fig. 6). Notably, this provided additional support for new CAC variants regulating *IGFBP3* (*rs2854746* and *rs924140*), *ENPP1* (*rs3844006*) and *ARID5B* and a known variant in the 9p21 locus (*rs1537373*) regulating *CDKN2B-AS1/CDKN2B* (Supplementary Table 11a, b). We confirmed these findings using our recent single-nucleus chromatin accessibility dataset in healthy and diseased coronary arteries³⁹, which identified credible CAC variants at *IGFBP3*,

ARID5B and *ENPP1* loci overlapping cell-type-specific peak-to-gene links (Fig. 3 and Supplementary Fig. 6). Notably, CAC-associated variants were most enriched in SMC accessible chromatin regions compared to other coronary artery cell types (Supplementary Table 12). These results demonstrate that several identified CAC GWAS signals map to relevant genes, particularly in SMCs in the vascular wall, and implicate candidate regulatory mechanisms for the CAC associations.

Mapping target pathways, cell types and plaque phenotypes

Using gene-set pathway enrichment analysis for the candidate CAC genes, we identified significant enrichment of bone mineralization regulation, vitamin D receptor and riboflavin metabolism pathways (Supplementary Table 13). We also identified enrichment of phosphate catabolism/homeostasis (*ENPP1/ENPP3* and *FGF23*) and hormone secretion (*FGF23*) pathways, suggesting that there could be unique genetic risk factors disrupting essential hormonal metabolic pathways that have been linked to mineralization and/or plaque stability⁴⁰.

We next investigated the overall expression profiles for the candidate CAC genes in bulk GTEx tissues (Supplementary Fig. 7). Many of the candidate genes (for example, *COL4A1/COL4A2*, *IGFBP3*, *ENPP1*




Fig. 3 | Single-nucleus coronary epigenomic annotation of *ARID5B* and *IGFBP3* CAC loci. a, b. Top: *ARID5B* (a) and *IGFBP3* (b) locus association plots showing CAC meta-analysis results in European and African American ancestry individuals with credible set SNPs color coded by posterior probability (red). Meta-analysis *P* values determined from weighted *z* scores in fixed-effects model and central association *P* values determined from chi-square test statistic.

Bottom: overlapping chromatin accessibility profiles in coronary artery cell types determined by bulk and single-nucleus ATAC-seq. Peak2gene links highlight predicted enhancer–promoter interactions across all cell types with those overlapping CAC SNPs shown in black. Light gray box highlights lead SNP at each locus. T/NK, T cells or natural killer cells.

and *ADAMTS7*) were expressed together in artery tissues relative to other tissues, suggesting shared cell type expression profiles. Thus, we explored the cellular distribution in single-cell gene expression data from atherosclerotic coronary artery^{41–43} and carotid plaques⁴⁴. Among the identified CAC genes, *ARID5B*, *COL4A2* and *CXCL12* were specifically expressed in SMCs and/or pericytes and *IGFBP3* was expressed in mesenchymal-like endothelial cells as well as fibroblast-like SMCs (Supplementary Fig. 8)⁴⁵. *ENPP1* and *ENPP3* were expressed in small proportions of SMCs and mast cells, respectively.

To gain insight into the pathobiology of the 16 lead CAC SNPs from FUMA, we assessed the association with advanced plaque morphology. We examined seven plaque morphological characteristics measured in atherosclerotic carotid plaques in the Athero-Express Biobank Study⁴⁶. *APOE* was associated with increased intraplaque fat content and vessel density and decreased collagen content, all known features of increased plaque vulnerability (Supplementary Table 14a). Individual variant analyses at the remaining loci were most significant for plaque calcification (adenosine kinase (*ADK*), *PHACTRI*), SMC (*ADK*, *CDKN2B-AS1*) and macrophage content (*CXCL12*), collagen deposition (*IGFBP3*) and intraplaque neovessel density (*PHACTRI*; Supplementary Table 14b). This suggests that there may be an overlap in the pathological hallmarks between the CAC- and CAD-associated genes in advanced plaques.

Heritability, genetic correlations and Mendelian randomization

We applied linkage disequilibrium score regression (LDSC)⁴⁷ to estimate the heritability of CAC in European ancestry study participants and observed that the genome-wide set of variants account for 16%

(s.e. = 2.5%) of the variance in CAC. This estimate represents almost half of the heritability estimated from phenotypic correlations among relatives^{16,17}. We expect the CAC heritability to be equivalent for individuals of African ancestry, based on a recent multi-ancestry GWAS meta-analysis for CAD⁴⁸.

We estimated the genetic correlation between CAC and clinical CVD, subclinical atherosclerosis, selected CVD risk factors and family history of CVD in individuals of European ancestry. There were significant genetic correlations between CAC and carotid plaque and abdominal aortic calcification as well as several clinical outcomes—including CAD and myocardial infarction—and risk factors such as high cholesterol, use of cholesterol-lowering medication, hypertension, body mass index (BMI), waist circumference and whole-body fat mass. There were also correlations with family history of CVD and age at parental death (Fig. 4 and Supplementary Table 15).

We then performed Mendelian randomization (MR) analysis to assess the potential causality of CVD risk factors with CAC. Low-density lipoprotein (LDL) cholesterol, triglycerides, systolic and diastolic blood pressure, BMI and type 2 diabetes were causally associated with an increase in CAC, while an increase in high-density lipoprotein (HDL) cholesterol was causally associated with a decrease in CAC (Fig. 4 and Supplementary Table 16a). Moreover, CAC was causally associated with clinical CAD when the 16 independently significant lead SNP from FUMA in 11 different loci for CAC were considered (Supplementary Table 16b). However, as expected, the association was diminished when restricted to the five CAC-specific loci (Supplementary Table 16c), suggesting that the effects on clinical CAD from all loci are likely driven by independent SNPs with large effects on CAD (for example, 9p21).




Fig. 4 | Genetic correlations for CAC and MR for CVD risk factors. a, Cross-trait LD-score regression-based genetic correlation of CAC quantity with CVD risk factors, anthropomorphic risk factors, family history, subclinical and clinical CVD using European ancestry CAC and UK Biobank trait associations. Vertical dashed line set at genetic covariance = 0. Values represent the genetic correlation estimates using the slope from the regression of the product of z scores from two GWAS studies on the LD score, and error bars represent the s.e. estimates of the LD score. P values (two-tailed) are computed from chi-square test statistics. **b**, MR results showing causal effects of CVD and anthropomorphic risk factors on CAC quantity using the IVW method. Values represent the mean

odds ratio (OR), and error bars reflect the 95% confidence intervals (CIs). P values (two-tailed t test) $< 7.14 \times 10^{-3}$ (0.05/7) are considered statistically significant. Vertical dashed line set at OR = 1.0. **c**, MR results showing causal effects of CAC quantity on CAD using either 16 independent lead SNPs at the 11 CAC loci or 5 lead SNPs from the 5 CAC-specific loci (separated by horizontal dashed line). Values represent the mean OR, and error bars reflect the 95% CIs. P values (two-tailed t test) < 0.05 are considered statistically significant. Different MR methods used are shown, including MR-Egger, IVW and weighted median. Sample sizes for **a–c** are provided in Supplementary Tables 15 and 16. cIMT, carotid intima-media thickness.

We performed weighted median estimator and MR-Egger regression analyses as sensitivity analyses to rule out potential bias caused by horizontal pleiotropy⁴⁹. While the associations showed robust effect estimates in similar directions, we cannot entirely rule out potential pleiotropic effects through shared cardiometabolic risk factors.

Functional characterization of CAC genes

Given the strong association between CAC and CAD, we further examined whether each of the candidate CAC genes is also associated at genome-wide significance with clinical CAD based on large-scale GWAS data from the CARDIoGRAMplusC4D Consortium, UK Biobank and Million Veteran Program^{21,50}. While a few of the candidate genes were associated with CAD as expected, among our eight new CAC loci (Table 1), several (*ENPP1/ENPP3*, *IGFBP3*, *ARID5B*, *ADK* and *FGF23*) have not yet been

reported to be associated with clinical CAD (Supplementary Table 17). We observed similar results in our PheWAS analysis considering only the eight new CAC loci (Supplementary Table 18).

We next evaluated the protein localization of the new CAC genes in subclinical and advanced atherosclerotic coronary artery sections ex vivo. ENPP1, IGFBP3 and ADK proteins were expressed in the medial vessel layer of both subclinical and advanced atherosclerotic human coronary arteries, as shown by immunofluorescence staining (Fig. 5). FGF23 was not detected in the coronary artery specimens, consistent with recent reports that its associations with CVD may be mediated by endocrine and paracrine effects⁵¹. ENPP1, IGFBP3, ARID5B and ADK proteins were all highly expressed in the neointima of diseased vessels, with ARID5B being more restricted to the intimal layer (Fig. 5). This provides evidence that some of these CAC-associated proteins are present




Fig. 5 | Immunofluorescence staining showing localization of ENPP1, IGFBP3, ARID5B and ADK in control and atherosclerotic human coronary arteries. **a,b**, Transverse sections of healthy control (**a**) and atherosclerotic (**b**) human coronary arteries were stained for alpha-smooth muscle actin (α -SMA; green), DAPI nuclei marker (blue), ENPP1/PC-1 (white), IGFBP3 (red), ARID5B (purple)

and ADK (yellow). High levels of ENPP1/PC-1, IGFBP3, ARID5B and ADK were observed in the neointimal layer of atherosclerotic diseased coronary arteries. Whole artery images were captured at $\times 10$ magnification, and regions of interest were captured at $\times 20$. Images are representative of $n = 4$ independent donors per group. Scale bars, 0.5 mm.

at the early stages of atherosclerosis and may directly participate in intimal calcification.

To examine the functional role of these four genes (*ENPP1*, *IGFBP3*, *ARID5B* and *ADK*) in vitro, HCASMCs were treated with small interfering RNAs (siRNAs) directed against these genes in the presence and absence of osteogenic media (OM). *FGF23* was not evaluated given its undetectable expression in HCASMCs. Compared to HCASMCs incubated in control media, cells grown in OM for 48 h exhibited a twofold increase in mRNA levels of *RUNX2*, a known master regulator of osteogenic phenotype switch in SMCs (Fig. 6a). Treatment of cells with siARID5B and siADK prevented the OM-induced increase in *RUNX2*; treatment with siRNA directed against *IGFBP3* also attenuated this increase (Fig. 6a and Supplementary Fig. 9). At the protein level, increased RUNX2 levels were observed with cells grown in OM compared to those grown in control media, while treatment with siRNA directed against *IGFBP3*, *ARID5B* or *ADK* attenuated this increase in RUNX2 (Fig. 6b). Similarly, treatment with siIGFBP3 and siADK prevented the OM-induced decrease in *CNN1* mRNA expression, thus promoting the contractile SMC phenotype (Fig. 6c). Treatment with

siIGFBP3, siARID5B and siADK resulted in inhibition of calcification, as assessed by Alizarin Red staining compared to siCTRL-treated cells (Fig. 6d). Of note, knockdown of *ENPP1* had no effect on *RUNX2*, *CNN1* or calcification levels. These results implicate *IGFBP3*, *ARID5B* and *ADK* in the development of an osteogenic phenotype, which is characterized by an increase in cell proliferation and migration. Treatment with siIGFBP3 resulted in decreased cell proliferation, as measured by MTT assay (Fig. 6e). Treatment with siIGFBP3 and siADK led to an expected decrease in cell migration, while siARID5B treatment was associated with greater migration (Fig. 6f,g). Taken together, these results indicate that *IGFBP3*, *ARID5B* and *ADK* have a key role in regulating VSMC phenotype and promoting VSMC calcification, which is consistent with the direction of the effect alleles from the CAC GWAS and eQTL signals for these genes.

Druggability analysis

To investigate the potential clinical utility of CAC candidate genes at the 11 independent risk loci, we performed an integrative druggability analysis (Supplementary Table 19a,b). Three loci were identified




Fig. 6 | Functional assays of *ENPP1*, *IGFBP3*, *ARID5B* and *ADK* in CAC and vascular SMC phenotype. **a, Effects of siRNA-mediated knockdown of *ENPP1*, *IGFBP3*, *ARID5B* and *ADK* on osteogenic marker *RUNX2* gene expression in HCASMCs cultured in control or OM. $n = 6$ biological replicates per group. **b**, Western blot analysis of *RUNX2* protein levels in HCASMCs cultured in basal control or OM and transfected with siCTRL, siENPP1, siIGFBP3, siARID5B or siADK. GAPDH was used as a loading control. **c**, Effects of siRNA knockdown on *CNN1* mRNA expression. $n = 6$ biological replicates per group. **d**, Calcification assessed by Alizarin Red staining in HCASMCs cultured in OM and transfected with siCTRL, siENPP1, siIGFBP3, siARID5B or siADK. Representative images from three independent experiments. **e**, MTT assay-based proliferation in HCASMCs**

transfected with siCTRL, siENPP1, siIGFBP3, siARID5B or siADK. $n = 12$ biological replicates per treatment and control group; each individual sample read three times; value reported represents the mean of three technical replicates. **f,g**, Scratch wound-based migration assay in HCASMCs transfected with siCTRL, siENPP1, siIGFBP3, siARID5B or siADK, as quantified in **g**. An initial image of the assay is provided to demonstrate creation of a cell-free gap, before incubation with OM. $n = 6$ biological replicates per treatment and control group. Scale bars, 200 μ m. All statistical comparisons shown were made using a two-tailed one-way ANOVA with Sidak's test for multiple comparisons. Values in **a–g** represent mean $\pm$ s.e. of the mean. Full-length blots are provided as source data.

as targets of clinically actionable compounds (*CDKN2B*, *ARID5B* and *FGF23*), which have the potential for repurposing approved drugs and informing clinical trials for CAC. Notably, *ENPP1/ENPP3*, *IGFBP3*, *ARID5B*, *ADK* and *FGF23* represent targets of the druggable genome, which should be considered for preclinical studies of CAC. By querying the

drug–gene interaction database (DGIdb) and DrugBank database, we found approved compounds under investigation targeting *IGFBP3*, *ADK* and *FGF23* (Fig. 7). For example, *IGFBP3* is a target of the biosynthetic hormone mecaseimerin and nonsteroidal anti-inflammatory drugs. We identified many targets of nutrient supplementation in late-stage




Fig. 7 | Schematic of CAC candidate genes and approved or investigational drugs. a, Summary of gene–drug interactions for CAC candidate genes using DGIdb and DrugBank databases. New CAC-specific genes are shown in blue and other genes are shown in light blue corresponding to each genomic locus. Generic names for the top interacting drugs/compounds are shown for each target in red. **b**, Schematic showing the cellular location of the protein targets

for new CAC genes. Names of interacting approved drugs or compounds under investigation are shown along with predicted pharmacological interaction if known. ECM, extracellular matrix; ATP, adenosine triphosphate; AMP, adenosine monophosphate; PPI, inorganic pyrophosphate; PEG, polyethylene glycol. Figure created in BioRender.

clinical trials for nutrient deficiencies associated with chronic metabolic diseases. For example, Burosumab (monoclonal antibody against *FGF23*) is being evaluated for hypophosphatemic rickets and chronic pain (NCT03581591) and X-linked hypophosphatemia (NCT04146935). Also, *ARID5B* was identified as a target of ascorbic acid (vitamin C). These findings offer preclinical, repurposing and prevention opportunities to modulate CAC via these targets, to slow CAD progression or even to promote plaque stability in advanced stages³².

Discussion

We identified 16 independent genome-wide significant variant associations for CAC at 11 distinct genomic loci in FUMA, including 8 loci not previously reported to be associated with CAC, by leveraging genome-wide genotypes from 35,776 participants (Table 1 and Fig. 1). Through integrating functional data with GWAS results as well as gene-based analyses, we identified a total of 43 candidate genes for CAC (Supplementary Table 20). Top pathways identified involve bone mineralization regulation, vitamin and phosphate metabolism, and hormone secretion. Notably, five of our eight new CAC loci have not been previously reported to be associated with clinical CAD. We provide *ex vivo* and/or *in vitro* functional validation for four of these genes (*ENPP1*, *IGFBP3*, *ARID5B* and *ADK*), supporting their causal role in CAC. Several of our CAC-associated genes are targets of drug or supplement interactions, revealing opportunities to study how these compounds may promote or inhibit CAC at different stages of atherosclerosis.

The CAC locus on 6q23.2 resides 26 kilobases (kb) and 34 kb upstream of paralog genes *ENPP3* and *ENPP1* (ectonucleotide pyrophosphatase/phosphodiesterase 3 and 1), respectively. *ENPP1* is one of the causal genes (along with *ABCC6*) of the spectrum of rare Mendelian arterial calcification diseases known as generalized arterial calcification of infancy and pseudoxanthoma elasticum^{53,54}. *ENPP1* and *ENPP3* have both been associated with phosphate levels in multiple studies⁵⁵,

while *ENPP1* has been associated with venous thromboembolism⁵⁶ and *ENPP3* with type 2 diabetes⁵⁷ and vitamin D levels⁵⁵. *ENPP1* and *ENPP3* are involved in bone mineralization and riboflavin metabolism pathways, suggesting common variants in this locus impact CAC through phosphate catabolism/homeostasis. While we did not observe direct functional effects of perturbing *ENPP1* expression in HCASMCs, it is expressed in the intima of atherosclerotic coronary arteries, suggesting enzymatic perturbation may be more fruitful. The druggability of these genes presents an opportunity to translate the genetic findings into treatments for CAC in the general population, particularly in the setting of type 2 diabetes.

The associated variant on 7p12.3 within *IGFBP3*, rs2854746, was supported by several lines of evidence, including positional and eQTL mapping, gene-based analyses and single-cell epigenomics. *IGFBP3* was previously associated with blood pressure traits^{58,59}, cellular fibronectin and NT-proBNP⁶⁰, anthropometric measures⁶¹, appendicular lean mass⁶² and bone mineral density⁶³. Our fine-mapping analyses provide strong evidence for *IGFBP3* to be implicated in vitamin D receptor metabolism. Consistent with this, our functional studies demonstrate direct effects on SMC calcification, proliferation and migration. In addition, *IGFBP3* is a target of the approved biosynthetic compound mecasermin. Given that IGFBP3 protein levels have been previously associated with the presence and extent of coronary atherosclerosis in a small study⁶⁴, there are both prognostic and therapeutic opportunities to explore further.

ARID5B is known to transcriptionally activate or repress metabolic gene expression⁶⁵ involved in adipogenesis and lipid metabolism⁶⁶ and mesenchymal cell differentiation during SMC phenotypic modulation⁶⁷. *ARID5B* is expressed in ACTA2⁺ SMCs and in endothelial cells marked by endothelial-to-mesenchymal transition⁴⁵, and epigenome-based fine-mapping identified *ARID5B* as a target gene in coronary and aortic tissue. Variants in *ARID5B* are associated with

coronary atherosclerosis⁶⁸ and type 2 diabetes⁶⁹ in smaller studies on a Japanese population, but also with measures of height and heel bone mineral density⁶³. *ARID5B* has been shown to promote chondrogenesis⁷⁰, and consistently our perturbation studies demonstrated potent effects on osteogenic marker expression, calcification and proliferation in SMCs. Our druggability analyses identified *ARID5B* as a clinically actionable target of phosphate-lowering vitamin C supplementation to evaluate variant angina and atheroma regression in a clinical trial (NCT03228238). Interestingly, *ARID5B* was the only new CAC locus not previously associated with CAD, harboring a significant gene–sex interaction, with a stronger effect in males. Future studies could explore whether this difference is related to distinct atherosclerotic plaque profiles in males compared to females.

Extensive positional and functional mapping analyses indicate that *ADK* is the causal gene for the CAC locus on 10q22.2. *ADK* is a protein-coding gene involved in regulating extracellular adenosine and intracellular adenine nucleotide levels. Adenosine has widespread effects on the cardiovascular, nervous, respiratory and immune systems⁷¹. Endothelial intracellular adenosine and its key regulator, *ADK*, have important roles in endothelial inflammation and vascular inflammatory diseases⁷². Loss of endothelial *Adk* in mice reduces atherosclerosis and leads to protection against ischemia/reperfusion injury in the cerebral cortex⁷². *Adk* knockout in myeloid cells and the resulting augmented intracellular adenosine levels protect *ApoE*^{−/−} mice against atherosclerosis⁷³. Further, *Adk* was upregulated along with *Enpp1* in the thoracic aorta of the *Abcc6* knockout mouse model of pseudoxanthoma elasticum, providing a functional link to arterial calcification⁷⁴. This aligns with our in vitro functional studies, demonstrating strong effects on SMC calcification and related osteogenic SMC phenotypes. *ADK*-modulating strategies could act as anti-inflammatory agents for treating atherosclerotic diseases⁷⁵.

FGF23 (12p13.32) is a well-studied protein-coding gene linked to vascular calcification in patients with chronic kidney disease on hemodialysis⁷⁶. It has been suggested that this may represent a paracrine-mediated homeostatic mechanism to maintain phosphorus levels⁷⁷. While *FGF23* may not be causally related to CAC⁷⁸, consistent with the absent expression in coronary artery cells/tissues, follow-up preclinical studies could investigate the effects of monoclonal antibody burosumab on calcification secondary to renal outcomes.

As the hallmark of atherosclerosis, CAC is strongly associated with future CAD events. Consistent with the shared etiology between CAC and CAD, several of our new CAC genes were previously reported in association with CAD. Our colocalization analyses also indicated a substantial overlap between prioritized genes in CAC and CAD. This is expected given that CAC is an integral component of both early intimal thickening and advanced atherosclerotic plaque, likely representing a ‘healing’ phase^{12,79}. Our MR analyses using 16 significant lead SNPs for CAC as instrumental variables provided evidence for a causal association between CAC and CAD events. However, several of our new CAC-associated genes, including *IGFBP3*, *FGF23*, *ENPP1/ENPP3*, *ARID5B* and *ADK*, have so far not been reported to be associated with CAD. In line with this, these genes showed strong evidence for colocalization with CAC but not with CAD. Clinical studies have shown that increased CAC is associated with future acute coronary syndrome; however, pathological evidence has demonstrated that CAC represents a marker of the extent of disease⁸⁰. It is suggested that stable, slowly progressive large plaques, leading to a negative remodeling of the vessel, do not readily correlate with the onset of symptoms and clinical CAD events⁸¹. In contrast, unstable plaques at high risk of producing symptomatic rupture carry highly inflamed fibrous caps and are not necessarily more stenotic⁸². Notably, some of our CAC candidate genes were implicated in pathways underlying bone mineralization regulation and associated with plaque stability features in advanced carotid plaque tissues. We also identified genes that may be involved in early lesions, based on

expression in mesenchymal or fibroblast-like SMCs that may precede osteogenic transitions.

CAC reflects the vessel’s accumulation of lifetime exposure to risk factors. While observational studies suggest a role for hypertension, higher BMI and type 2 diabetes in the development and progression of CAC⁸³, evidence regarding the association of an unfavorable lipid profile with coronary calcification, in particular progression of CAC, remains unclear^{84,85}. Moreover, important questions remain about the causality of these risk factors. We found evidence of significant genetic correlations between CAC quantity and high cholesterol, cholesterol-lowering medication use, hypertension, BMI, waist circumference and whole-body fat mass. Our MR analyses further provided evidence for a causal association between modifiable CVD risk factors, including LDL and HDL cholesterol, triglycerides, type 2 diabetes and BMI, with CAC quantity. These findings emphasize the value of optimal risk factor control for reducing atherosclerosis burden and further extend our knowledge of the pathways underlying coronary calcification.

Our GWAS meta-analysis requires replication and includes only individuals of European and African ancestry. Future multi-ancestry meta-analyses will benefit from larger sample sizes, diverse ancestral populations and use of larger, more diverse reference imputation panels such as TOPMed to provide replication of our significant new loci as well as the discovery of new CAC loci. Future studies should also include the X chromosome because a very recent study identified new variants on the X chromosome associated with CAD⁴⁸. Future stratified analyses based on ancestry, sex and risk factors (for example, smoking) may provide further insights into interindividual differences in CAC risk. Smoking is particularly important to consider given the interaction between a variant upstream of the *ADAMT7* gene and smoking on clinical CAD in a candidate gene study⁸⁶. A small GWAS of gene-by-smoking interaction also demonstrated the potential to identify new genes for CAC⁸⁷.

There are many strengths to our study, which employed a series of complementary statistical, functional fine-mapping and ex vivo and in vitro experimental validation studies. We used several unique atherosclerotic tissue biobanks, which were derived from patients during surgical procedures and provide a more relevant context to the effector genes, plaque phenotypes and cell types. Finally, we employed ex vivo and in vitro functional validation assays and druggability analyses to help inform translational strategies and identify cell-specific mechanisms for these candidate targets. Notably, *IGFBP3*, *ARID5B* and *ADK* were shown to promote calcification in HCASMCs, consistent with changes in gene expression, related SMC phenotypes and protein expression in atherosclerotic coronary arteries.

In summary, we discovered eight new loci associated with CAC, thus doubling the total known CAC loci to date. Extensive post-GWAS fine-mapping and annotation provided evidence for cell- and disease-specific expression of *IGFBP3*, *FGF23*, *ENPP1/ENPP3*, *ADK* and *ARID5B* in coronary and carotid arterial plaque tissue. Notably, many of these genes encode proteins identified as predicted targets of approved drugs or investigational compounds. While we provide evidence supporting the causal role of some of these CAC-associated genes, additional functional analyses may support other candidate genes. Future studies should elucidate the molecular mechanisms of these genes in the cells of the arterial wall, evaluate their function in preclinical animal models of atherosclerosis and focus on creating a saturated map of common and rare variants influencing CAC through the inclusion of diverse ancestries.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41588-023-01518-4>.

References

1. Timmis, A. et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. *Eur. Heart J.* **39**, 508–579 (2018).
2. Tsao, C. W. et al. Heart Disease and Stroke Statistics—2022 Update: a report from the American Heart Association. *Circulation* **145**, e153–e639 (2022).
3. Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. *Nature* **473**, 317–325 (2011).
4. Baber, U. et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BiImage study. *J. Am. Coll. Cardiol.* **65**, 1065–1074 (2015).
5. Polonsky, T. S. et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. *JAMA* **303**, 1610–1616 (2010).
6. Kavousi, M. et al. Evaluation of newer risk markers for coronary heart disease risk classification. *Ann. Intern. Med.* **156**, 438–444 (2012).
7. Bielak, L. F., Rumberger, J. A., Sheedy, P. F. 2nd, Schwartz, R. S. & Peyser, P. A. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. *Circulation* **102**, 380–385 (2000).
8. Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* **139**, e1082–e1143 (2019).
9. Jin, H.-Y. et al. The relationship between coronary calcification and the natural history of coronary artery disease. *JACC Cardiovasc. Imaging* **14**, 233–242 (2021).
10. Jinnouchi, H. et al. Calcium deposition within coronary atherosclerotic lesion: implications for plaque stability. *Atherosclerosis* **306**, 85–95 (2020).
11. Durham, A. L., Speer, M. Y., Scatena, M., Giachelli, C. M. & Shanahan, C. M. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. *Cardiovasc. Res.* **114**, 590–600 (2018).
12. Nakahara, T. et al. Coronary artery calcification: from mechanism to molecular imaging. *JACC Cardiovasc. Imaging* **10**, 582–593 (2017).
13. Fujiyoshi, A. et al. Coronary artery calcium and risk of dementia in mesa (multi-ethnic study of atherosclerosis). *Circ. Cardiovasc. Imaging* **10**, e005349 (2017).
14. Handy, C. E. et al. The association of coronary artery calcium with noncardiovascular disease: the multi-ethnic study of atherosclerosis. *JACC Cardiovasc. Imaging* **9**, 568–576 (2016).
15. Hermann, D. M. et al. Coronary artery calcification is an independent stroke predictor in the general population. *Stroke* **44**, 1008–1013 (2013).
16. Peyser, P. A. et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. *Circulation* **106**, 304–308 (2002).
17. Wojczynski, M. K. et al. Genetics of coronary artery calcification among African Americans, a meta-analysis. *BMC Med. Genet.* **14**, 75 (2013).
18. Natarajan, P. et al. Multiethnic exome-wide association study of subclinical atherosclerosis. *Circ. Cardiovasc. Genet.* **9**, 511–520 (2016).
19. O'Donnell, C. J. et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. *Circulation* **124**, 2855–2864 (2011).
20. Van Setten, J. et al. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. *Atherosclerosis* **228**, 400–405 (2013).
21. Nelson, C. P. et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat. Genet.* **49**, 1385–1391 (2017).
22. Psaty, B. M. et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ. Cardiovasc. Genet.* **2**, 73–80 (2009).
23. Agatston, A. S. et al. Quantification of coronary artery calcium using ultrafast computed tomography. *J. Am. Coll. Cardiol.* **15**, 827–832 (1990).
24. Shen, H. et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the Old Order Amish. *Arch. Intern. Med.* **170**, 1850–1855 (2010).
25. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
26. Wellcome Trust Case Control Consortium et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294–1301 (2012).
27. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
28. De Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
29. Weeks, E. M. et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. *Nat. Genet.* **55**, 1267–1276 (2023).
30. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
31. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
32. Franzén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. *Science* **353**, 827–830 (2016).
33. Franceschini, N. et al. GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. *Nat. Commun.* **9**, 5141 (2018).
34. Hao, K. et al. Integrative prioritization of causal genes for coronary artery disease. *Circ. Genom. Precis. Med.* **15**, e003365 (2022).
35. Cano-Gamez, E. & Trynka, G. From GWAS to function: using functional genomics to identify the mechanisms underlying complex diseases. *Front. Genet.* **11**, 424 (2020).
36. Liu, B. et al. Genetic regulatory mechanisms of smooth muscle cells map to coronary artery disease risk loci. *Am. J. Hum. Genet.* **103**, 377–388 (2018).
37. Fulco, C. P. et al. Activity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations. *Nat. Genet.* **51**, 1664–1669 (2019).
38. Liu, Y., Sarkar, A., Kheradpour, P., Ernst, J. & Kellis, M. Evidence of reduced recombination rate in human regulatory domains. *Genome Biol.* **18**, 193 (2017).
39. Turner, A. W. et al. Single-nucleus chromatin accessibility profiling highlights regulatory mechanisms of coronary artery disease risk. *Nat. Genet.* **54**, 804–816 (2022).
40. Shen, J. et al. Regulation of vascular calcification by growth hormone-releasing hormone and its agonists. *Circ. Res.* **122**, 1395–1408 (2018).
41. Pan, H. et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. *Circulation* **142**, 2060–2075 (2020).
42. Wirka, R. C. et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. *Nat. Med.* **25**, 1280–1289 (2019).

43. Alsaigh, T., Evans, D., Frankel, D. & Torkamani, A. Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution. *Commun. Biol.* **5**, 1084 (2022).
44. Slenders, L. et al. Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis. *Eur. Heart J. Open* **2**, oeab043 (2021).
45. Depuydt, M. A. C. et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. *Circ. Res.* **127**, 1437–1455 (2020).
46. Van der Laan, S. W. et al. Genetic susceptibility loci for cardiovascular disease and their impact on atherosclerotic plaques. *Circ. Genom. Precis. Med.* **11**, e002115 (2018).
47. Bulik-Sullivan, B. K. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
48. Tcheandjie, C. et al. Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. *Nat. Med.* **28**, 1679–1692 (2022).
49. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum. Mol. Genet.* **27**, R195–R208 (2018).
50. Van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ. Res.* **122**, 433–443 (2018).
51. Donovan, K. et al. Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study. *Clin. J. Am. Soc. Nephrol.* **18**, 17–27 (2023).
52. Hall, K. T. et al. Catechol-O-methyltransferase and cardiovascular disease: MESA. *J. Am. Heart Assoc.* **8**, e014986 (2019).
53. Nitschke, Y. et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. *Am. J. Hum. Genet.* **90**, 25–39 (2012).
54. Ralph, D. et al. ENPP1 variants in patients with GACI and PXE expand the clinical and genetic heterogeneity of heritable disorders of ectopic calcification. *PLoS Genet.* **18**, e1010192 (2022).
55. Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat. Genet.* **53**, 185–194 (2021).
56. Herrera-Rivero, M. et al. Single- and multimarker genome-wide scans evidence novel genetic risk modifiers for venous thromboembolism. *Thromb. Haemost.* **121**, 1169–1180 (2021).
57. Spracklen, C. N. et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals. *Nature* **582**, 240–245 (2020).
58. Kato, N. et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat. Genet.* **47**, 1282–1293 (2015).
59. Giri, A. et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat. Genet.* **51**, 51–62 (2019).
60. Thériault, S. et al. Identification of circulating proteins associated with blood pressure using Mendelian randomization. *Circ. Genom. Precis. Med.* **13**, e002605 (2020).
61. Kichaev, G. et al. Leveraging polygenic functional enrichment to improve GWAS power. *Am. J. Hum. Genet.* **104**, 65–75 (2019).
62. Hernandez Cordero, A. I. et al. Genome-wide associations reveal human-mouse genetic convergence and modifiers of myogenesis, CPNE1 and STC2. *Am. J. Hum. Genet.* **105**, 1222–1236 (2019).
63. Kim, S. K. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PLoS ONE* **13**, e0200785 (2018).
64. Schuler-Lüttmann, S. et al. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **20**, e10–e15 (2000).
65. Claussnitzer, M. et al. FTO obesity variant circuitry and adipocyte browning in humans. *N. Engl. J. Med.* **373**, 895–907 (2015).
66. Whitson, R. H. Jr, Li, S.-L., Zhang, G., Larson, G. P. & Itakura, K. Mice with Fabp4-Cre ablation of Arid5b are resistant to diet-induced obesity and hepatic steatosis. *Mol. Cell. Endocrinol.* **528**, 111246 (2021).
67. Watanabe, M. et al. Regulation of smooth muscle cell differentiation by AT-rich interaction domain transcription factors Mrf2a and Mrf2b. *Circ. Res.* **91**, 382–389 (2002).
68. Wang, G. et al. Genetic variations of Mrf-2/ARID5B confer risk of coronary atherosclerosis in the Japanese population. *Int. Heart J.* **49**, 313–327 (2008).
69. Wang, G. et al. Associations of variations in the MRF2/ARID5B gene with susceptibility to type 2 diabetes in the Japanese population. *J. Hum. Genet.* **57**, 727–733 (2012).
70. Hata, K. et al. Arid5b facilitates chondrogenesis by recruiting the histone demethylase Phf2 to Sox9-regulated genes. *Nat. Commun.* **4**, 2850 (2013).
71. Paganelli, F., Gaudry, M., Ruf, J. & Guieu, R. Recent advances in the role of the adenosinergic system in coronary artery disease. *Cardiovasc. Res.* **117**, 1284–1294 (2021).
72. Xu, Y. et al. Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. *Nat. Commun.* **8**, 943 (2017).
73. Zhang, M. et al. Ablation of myeloid ADK (adenosine kinase) epigenetically suppresses atherosclerosis in ApoE^{−/−} (apolipoprotein E deficient) mice. *Arterioscler. Thromb. Vasc. Biol.* **38**, 2780–2792 (2018).
74. Kauffenstein, G. et al. Alteration of extracellular nucleotide metabolism in pseudoxanthoma elasticum. *J. Invest. Dermatol.* **138**, 1862–1870 (2018).
75. Boison, D. Adenosine kinase: exploitation for therapeutic gain. *Pharmacol. Rev.* **65**, 906–943 (2013).
76. Ozkok, A. et al. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. *BMC Nephrol.* **14**, 241 (2013).
77. Murali, S. K. et al. FGF23 regulates bone mineralization in a 1,25(OH)₂D₃ and Klotho-independent manner. *J. Bone Miner. Res.* **31**, 129–142 (2016).
78. Donovan, K. et al. Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomisation study. *Clin. J. Am. Soc. Nephrol.* **18**, 17–27 (2023).
79. Alexopoulos, N. & Raggi, P. Calcification in atherosclerosis. *Nat. Rev. Cardiol.* **6**, 681–688 (2009).
80. Arbab-Zadeh, A. & Fuster, V. The myth of the ‘vulnerable plaque’: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. *J. Am. Coll. Cardiol.* **65**, 846–855 (2015).
81. Schoenhagen, P. et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. *Circulation* **101**, 598–603 (2000).
82. Mauriello, A. et al. Coronary calcification identifies the vulnerable patient rather than the vulnerable plaque. *Atherosclerosis* **229**, 124–129 (2013).
83. Nicoll, R., Zhao, Y., Ibrahim, P., Olivecrona, G. & Henein, M. Diabetes and hypertension consistently predict the presence and extent of coronary artery calcification in symptomatic patients: a systematic review and meta-analysis. *Int. J. Mol. Sci.* **17**, 1481 (2016).
84. Van der Toorn, J. E. et al. Arterial calcification at multiple sites: sex-specific cardiovascular risk profiles and mortality risk—the Rotterdam Study. *BMC Med.* **18**, 263 (2020).
85. Kronmal, R. A. et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the multi-ethnic study of atherosclerosis (MESA). *Circulation* **115**, 2722–2730 (2007).

86. Saleheen, D. et al. Loss of cardioprotective effects at the ADAMTS7 locus as a result of gene–smoking interactions. *Circulation* **135**, 2336–2353 (2017).
87. Polfus, L. M. et al. Genome-wide association study of gene by smoking interactions in coronary artery calcification. *PLoS ONE* **8**, e74642 (2013).

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023

Maryam Kavousi^{1,69}✉, Maxime M. Bos^{1,69}, Hanna J. Barnes^{2,69}, Christian L. Lino Cardenas^{2,69}, Doris Wong^{3,4,69}, Haojie Lu^{1,5,69}, Chani J. Hodonsky^{4,69}, Lennart P. L. Landsmeer^{6,69}, Adam W. Turner⁴, Minjung Kho^{7,8}, Natalie R. Hasbani⁹, Paul S. de Vries⁹, Donald W. Bowden¹⁰, Sandesh Chopade^{11,12}, Joris Deelen^{13,14}, Ernest Diez Benavente¹⁵, Xiuqing Guo¹⁶, Edith Hofer^{17,18}, Shih-Jen Hwang¹⁹, Sharon M. Lutz²⁰, Leo-Pekka Lyytikäinen²¹, Lotte Slenders⁶, Albert V. Smith^{22,23}, Maggie A. Stanislawski²⁴, Jessica van Setten²⁵, Quenna Wong²⁶, Lisa R. Yanek²⁷, Diane M. Becker^{27,70}, Marian Beekman¹³, Matthew J. Budoff¹⁶, Mary F. Feitosa²⁸, Chris Finan^{11,12,25}, Austin T. Hilliard²⁹, Sharon L. R. Kardia⁷, Jason C. Kovacic^{30,31,32}, Brian G. Kral²⁷, Carl D. Langefeld³³, Lenore J. Launer³⁴, Shaista Malik³⁵, Firdaus A. A. Mohamed Hoessein³⁶, Michal Mokry^{6,15}, Reinhold Schmidt¹⁷, Jennifer A. Smith^{7,37}, Kent D. Taylor¹⁶, James G. Terry³⁸, Jeroen van der Grond³⁹, Joyce van Meurs^{1,5}, Rozemarijn Vliegthart⁴⁰, Jianzhao Xu¹⁰, Kendra A. Young⁴¹, Nuno R. Zilhão²³, Robert Zweiker^{42,71}, Themistocles L. Assimes^{10,29,43}, Lewis C. Becker²⁷, Daniel Bos^{1,44}, J. Jeffrey Carr⁵, L. Adrienne Cupples^{45,72}, Dominique P. v. de Kleijn⁴⁶, Menno de Winther⁴⁷, Hester M. den Ruijter¹⁵, Myriam Fornage⁴⁸, Barry I. Freedman⁴⁹, Vilmundur Gudnason^{10,23,50}, Aroon D. Hingorani^{11,12}, John E. Hokanson⁴³, M. Arfan Ikram¹, Ivana Išgum^{51,52}, David R. Jacobs Jr.⁵³, Mika Kähönen⁵⁴, Leslie A. Lange²⁴, Terho Lehtimäki²¹, Gerard Pasterkamp⁶, Olli T. Raitakari^{55,56,57}, Helena Schmidt⁵⁸, P. Eline Slagboom¹³, André G. Uitterlinden^{1,5}, Meike W. Vernooij^{1,46}, Joshua C. Bis⁵⁹, Nora Franceschini⁶⁰, Bruce M. Psaty^{59,61}, Wendy S. Post^{62,63}, Jerome I. Rotter¹⁶, Johan L. M. Björkegren^{64,65}, Christopher J. O'Donnell^{66,67}, Lawrence F. Bielak^{7,73}, Patricia A. Peyser^{7,73}, Rajeev Malhotra^{2,73}, Sander W. van der Laan^{6,73} & Clint L. Miller^{3,4,68,73}✉

¹Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ²Cardiovascular Research Center, Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ³Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA. ⁴Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA. ⁵Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁶Central Diagnostics Laboratory, Division Laboratories, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ⁷Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. ⁸Graduate School of Data Science, Seoul National University, Seoul, Republic of Korea. ⁹Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Center at Houston, Houston, TX, USA. ¹⁰Department of Biochemistry, Wake Forest University Health Sciences, Winston-Salem, NC, USA. ¹¹Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, UK. ¹²University College London British Heart Foundation Research Accelerator Centre, London, UK. ¹³Biomedical Data Sciences, Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. ¹⁴Max Planck Institute for Biology of Aging, Cologne, Germany. ¹⁵Laboratory of Experimental Cardiology, Division of Heart and Lungs, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands. ¹⁶The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation (formerly Los Angeles Biomedical Research Institute) at Harbor-UCLA Medical Center, Torrance, CA, USA. ¹⁷Department of Neurology, Clinical Division of Neurogeriatrics, Medical University of Graz, Graz, Austria. ¹⁸Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria. ¹⁹Population Sciences, NHLBI/NIH, Framingham, MA, USA. ²⁰Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA. ²¹Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ²²Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ²³Icelandic Heart Association, Kopavogur, Iceland. ²⁴Department of Biomedical Informatics, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. ²⁵Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands. ²⁶Department of Biostatistics, University of Washington, Seattle, WA, USA. ²⁷GeneSTAR Research Program, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²⁸Department of Genetics, Division of Statistical Genomics, Washington University School of Medicine, St. Louis, MO, USA. ²⁹VA Palo Alto Healthcare System, Palo Alto, CA, USA. ³⁰Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia. ³¹St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia. ³²The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ³³Department of Biostatistical Sciences and Data Science, Wake Forest University Health Sciences, Winston-Salem, NC, USA. ³⁴Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. ³⁵Susan Samueli Integrative Health Institute, Department of Medicine, University of California Irvine, Irvine, CA, USA. ³⁶Department of Radiology, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands. ³⁷Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. ³⁸Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. ³⁹Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. ⁴⁰Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ⁴¹Department of Epidemiology, University of Colorado, Anschutz Medical Campus, Denver, CO, USA. ⁴²Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria. ⁴³Department of Medicine, Division of Cardiovascular Medicine,

Stanford University School of Medicine, Stanford, CA, USA. ⁴⁴Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁴⁵Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA. ⁴⁶Department of Vascular Surgery, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands. ⁴⁷Department of Medical Biochemistry, Experimental Vascular Biology, Amsterdam Cardiovascular Sciences: Atherosclerosis and Ischemic syndromes, Amsterdam Infection and Immunity: Inflammatory diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁴⁸Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. ⁴⁹Department of Internal Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA. ⁵⁰Faculty of Medicine, School of Public Health, University of Iceland, Reykjavik, Iceland. ⁵¹Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands. ⁵²Department of Biomedical Engineering and Physics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁵³Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. ⁵⁴Department of Clinical Physiology, Tampere University Hospital and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ⁵⁵Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland. ⁵⁶Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland. ⁵⁷Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland. ⁵⁸Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging), Medical University of Graz, Graz, Austria. ⁵⁹Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. ⁶⁰Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA. ⁶¹Departments of Epidemiology, and Health Systems and Population Health, University of Washington, Seattle, WA, USA. ⁶²Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁶³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁶⁴Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ⁶⁵Department of Medicine, Integrated Cardio Metabolic Centre, Karolinska Institutet, Huddinge, Sweden. ⁶⁶Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ⁶⁷Cardiology Section, Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, MA, USA. ⁶⁸Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. ⁶⁹These authors contributed equally: Maryam Kavousi, Maxime M. Bos, Hanna J. Barnes, Christian L. Lino Cardenas, Doris Wong, Haojie Lu, Chani J. Hodonsky, Lennart P. L. Landsmeer. ⁷⁰These authors jointly supervised this work: Lawrence F. Bielak, Patricia A. Peyser, Rajeev Malhotra, Sander W. van der Laan, Clint L. Miller. ⁷¹Deceased: Diane M. Becker. ⁷²Deceased: Robert Zweiker. ⁷³Deceased: L. Adrienne Cupples. ✉e-mail: m.kavousi@erasmusmc.nl; clintm@virginia.edu

Methods

Ethics statement

All human research was approved by the relevant institutional review boards (IRB) for each study and conducted according to the Declaration of Helsinki. All participants provided written informed consent (see Supplementary Table 22 for details).

Study populations and CAC assessment

The GWAS for CAC included 16 different cohorts. These cohorts contributed 26,909 participants of exclusively European ancestry and 8,867 participants of African ancestry. The descriptive characteristics of the participants are shown in Supplementary Table 1. All cohorts followed standardized protocols for the ascertainment of CAC quantity and statistical analyses. CAC was evaluated using computed tomography as explained in Supplementary Table 1. We used data from the baseline examination or the first examination in which CAC was assessed.

Genotyping, imputation and study-level quality control

Association analyses were performed using standardized protocols (Supplementary Note). Within each study, linear regression was used to model CAC quantity (that is, $\log(\text{CAC} + 1)$) with an additive genetic model (SNP dosage) adjusted for age, sex and up to 10 principal components. Extensive quality control (QC) was applied to the data. Genotyping arrays and QC preimputation are shown in Supplementary Table 1. Each study conducted genome-wide imputation using a Phase 1-integrated (March 2012 release) reference panel from the 1000G Consortium using IMPUTE or MaCH/minimac and used Human Reference Genome Build 37. There was little evidence for population stratification in any of the studies (Supplementary Table 21). Sample QC was performed with exclusions based on call rates, extreme heterozygosity, sex discordance, cryptic relatedness and outlying ancestry. SNP QC excluded variants based on call rates across samples and extreme deviation from Hardy–Weinberg equilibrium (Supplementary Table 21). Nonautosomal SNPs were excluded from imputation and association analysis. We used the EasyQC R package (v23.8) to perform QC for each study before the meta-analysis and excluded markers absent in the 1000G reference panel as follows: no-A/C/G/T/D/I markers; duplicate markers with low call rate; monomorphic SNPs and those with missing values in alleles, allele frequency and/or β estimates; SNPs with large effect estimates or $\text{s.e.} \geq 10$ and SNPs with allele frequency difference > 0.3 compared to 1000G global reference panel.

Meta-analysis

A joint meta-analysis of all available CAC GWAS was performed using fixed-effects meta-analysis in METAL, using SNP P values weighted by sample size. Summary statistics from each study were combined using an inverse variance-weighted (IVW) meta-analysis. Additional filters were applied during meta-analyses based on imputation quality (MAF, $r^2 < 0.3$ and IMPUTE info < 0.4), a minor allele frequency < 0.01 and SNPs that were not present in at least four studies or in both ancestry groups. Moreover, the variants with heterogeneity $I^2 \geq 70\%$ in the meta-analysis were excluded, leaving 8,586,047 variants. The genome-wide significance threshold was considered at $P < 5.0 \times 10^{-8}$.

We further conducted *trans*-ancestry meta-analyses using MR-MEGA (v0.2)⁸⁸ to account for potential heterogeneity at our lead SNPs. MR-MEGA uses multidimensional scaling of allele frequencies across all the cohorts to derive principal axes of genetic variation that can be used for ancestry adjustment. Using one principal component, which captured all of the population structure in the dataset, we estimated the heterogeneity of ancestry-associated ($P_{\text{value_ancestry_het}}$) and residuals ($P_{\text{value_residual_het}}$) for each lead SNP.

Gene–sex interaction analysis

We performed a sex-stratified meta-analysis at our 11 genome-wide significant CAC loci using the lead SNPs for a subset of cohorts

(~75% total sample; 10 European ancestry cohorts with 9,058 males and 10,132 females and 3 African ancestry cohorts with 1,816 males and 1,873 females) with reported sex-stratified GWAS results, following a similar approach used for the sex combined analyses with all cohorts (same additive model and fixed-effects model in METAL). We tested the difference of the results between the two strata using EasyStrata^{89,90}. The SNP–sex interaction was assessed by extracting a two-tailed P value from the z score using the following equation:

$$\frac{\beta_1 - \beta_2}{\sqrt{\text{s.e.}(\beta_1)^2 + \text{s.e.}(\beta_2)^2}}$$

Here β_1 and β_2 are the estimated CAC effect sizes for the SNPs in males and females separately, and $\text{s.e.}(\beta_1)$ and $\text{s.e.}(\beta_2)$ are the s.e. for the β estimated from males and females. The interaction test of the two groups was performed within the combined ancestry populations, and the results are shown in Supplementary Table 3. Sex-specific GWAS and SNP–sex interaction analyses were determined to be significant at $P < 4.54 \times 10^{-3}$ (Bonferroni correction for 11 tests).

Genomic risk loci definition

We used FUMA version v1.3.6a to obtain the genomic risk loci and functional information for the relevant SNPs in these loci based on 1000G Phase 3 (version 5 based on ALL populations). FUMA combines several external data sources to provide comprehensive annotation information. First, independent significant SNPs, at $P < 5 \times 10^{-8}$ and an LD at $r^2 < 0.6$ were identified through LD-based clumping in FUMA. The independent genomic risk loci were defined by identifying all SNPs in LD ($r^2 \geq 0.6$) with and in a region of 250 kb around one of the independent significant SNPs. We further defined the lead SNPs in each genomic risk locus as a subset of the independent significant SNPs that were in approximate LD with each other at $r^2 < 0.1$ through LD-based clumping. In naming the nearest genes for the independent loci, we mapped the nearest gene (protein coding or noncoding) to the lead SNP based on the physical location to the transcription start sites (TSS). We also assigned the nearest protein-coding genes at these loci using canonical TSS from GENCODE (v30) in ANNOVAR functional annotator (version 24 October 2019)⁹¹.

Genome-wide gene-based analysis

We performed gene-based analyses to summarize SNP associations at the gene level to map these gene sets to biological pathways. We used MAGMA v1.08 (ref. 28) through FUMA to perform gene-based analyses using the summary statistics of the combined meta-analysis in a window of 50 kb around 19,177 protein-coding genes (mapped to GRCh37/hg19 based on Ensembl 92). We used default settings to calculate empirical P values derived from 1,000 permutations and set a nominal P value conservatively at $0.05/19,177 = 2.61 \times 10^{-6}$. MAGMA leverages the per-variant test statistics by applying a multiple regression model to derive an empirical P value for the association of individual genes considering the LD structure that exists among variants and potential multimarker effects²⁸.

To further prioritize candidate genes, we also ran PoPS (v2.0)²⁹ using gene expression information from relevant human tissues. The above MAGMA gene annotation and scores for European-ancestry-only GWAS summary statistics were generated with FUMA and features included from GTEx v8 coronary artery, aorta and tibial artery tissues and no controls were used; otherwise, default settings were used as described in <https://github.com/FinucaneLab/pops> (accessed 15 March 2023).

eQTL-based fine mapping

To identify causal genes at CAC loci, we used two eQTL-based statistical fine-mapping methods, SMR³⁰ and coloc (v5.1.0)³¹. We integrated the European ancestry CAC GWAS summary statistics with eQTL summary

data from the STARNET cohort (European ancestry) of the following seven cardiometabolic tissues: AOR, whole blood (blood), LIV, MAM, subcutaneous fat, visceral fat and skeletal muscle, derived from ~600 individuals³², with a focus on AOR, MAM and LIV tissues. We first used SMR to test whether top CAC GWAS variants influence the phenotype through the perturbation of gene expression in these atherosclerosis relevant tissues. We considered only genes with at least one *cis*-eQTL $P < 5 \times 10^{-5}$ for colocalization. To account for a model of linkage, where two distinct signals drive the association with gene expression and CAC, we used the 1000G EUR LD reference panel and the post hoc HEIDI test 1 to exclude loci with evidence of linkage or heterogeneity in the genetic instruments. We performed the SMR/HEIDI test on 5,233 and 5,293 eGenes ($P_{\text{eQTL}} < 5 \times 10^{-5}$) in AOR and MAM tissues, respectively, to identify genes that passed a *Q* value⁹² threshold < 0.10 (AOR: $P_{\text{SMR}} < 3 \times 10^{-4}$, MAM: $P_{\text{SMR}} < 4 \times 10^{-4}$) and HEIDI test ($P_{\text{HEIDI}} > 0.01$).

We also performed a colocalization analysis using the R-based package, *coloc*³¹. This Bayesian statistical approach calculates the posterior probability that the CAC GWAS and eQTL data from different STARNET tissues share a common signal under the one causal variant assumption. Following a filtering step to include only eQTLs with $P < 0.05$, we tested for colocalization between overlapping variants in the CAC GWAS and STARNET expression data. We considered $PP4 > 0.8$ as strong evidence of colocalization. We considered strongly colocalized loci for CAC as those having $PP4 > 0.8$ for CAC but $PP4 < 0.5$ for CAD and strongly shared colocalized loci as those having $PP4 > 0.8$ for both traits.

Single-nuclear ATAC-seq (snATAC-seq) analysis

Atherosclerotic coronary artery segments were obtained from explanted hearts from 41 patients undergoing heart transplantation or donor hearts procured for research purposes at Stanford University. All samples were collected under IRB approval and written informed consent. Frozen tissues were transferred to the University of Virginia through a material transfer agreement and IRB-approved protocols and stored at -80°C until day-of-processing. For snATAC-seq analysis of human coronary artery samples, nuclei were isolated from frozen tissues, purified over an Opti-Prep iodixanol-based gradient as described³⁹ and subjected to 10X Genomics-based library preparation and sequencing on a NovaSeq 6000 (paired end, 2×50 bp) to achieve ~50,000 unique fragments per cell. Initial preprocessing was performed using the $\times 10$ Genomics pipeline (Cell Ranger ATAC v1.2.0). All ATAC-seq reads were mapped to the human genome reference hg38 build using the default parameters. Approximately 28,000 cells were included in the clustering analysis after filtering for high-quality cells with TSS enrichment > 7.0 and $> 10,000$ fragments using the ArchR package (v1.0.1) package⁹³. ArchR was also used for downstream analyses including dimensionality reduction, clustering, calculation of imputed gene scores and peak2gene links as described³⁹. snATAC tracks were visualized on the UCSC browser and compared with existing bulk coronary artery ATAC-seq tracks.

We used the LDSC package (<https://github.com/bulik/ldsc>) to perform LDSC on our published snATAC-seq peaks and the European ancestry CAC summary statistics. The *munge_sumstats.py* script was used to convert the summary statistics to a compatible format for LDSC. For each coronary artery cell type, we lifted over bed file peak coordinates from hg38 to hg19. The hg19 bed files were then used to make annotation files for each cell type. We performed LDSC according to the cell-type-specific analysis tutorial (<https://github.com/bulik/ldsc/wiki/Cell-type-specific-analyses>).

Gene-set pathway enrichment analysis

Gene-set pathway enrichment analyses were first performed in MAGMA²⁸ using both European ancestry and African ancestry CAC summary statistics (both unfiltered and subset to $P < 1 \times 10^{-5}$). Gene-based *P* values were computed based on the total sample size and a gene

annotation window of 2 kb upstream and 1 kb downstream of candidate genes. Mapped genes were used for MAGMA gene-set enrichment analyses against the 10,678 gene sets (curated, GO terms and MsigDB v6.2). GTEx v8 tissues, including blood vessel tissues (coronary, aorta and tibial artery), were used for the MAGMA gene-property analysis for tissue specificity. We also imported CAC strongly colocalized and CAC/CAD shared colocalized gene sets into enrichR (2020 update) to determine enriched pathways using a combination of databases including BioPlanet, BioCarta, KEGG, WikiPathways, Reactome and PANTHER⁹⁴.

Carotid plaque analyses

Atherosclerotic plaques were obtained from patients undergoing a carotid endarterectomy procedure and included in the Athero-Express Biobank Study (AE, approved and registered under number TME/C-01.18), an ongoing biobank study in Utrecht, The Netherlands⁹⁵. The study design of the AE has been described before,⁹⁵ however, in brief, during surgery both blood and plaques are obtained, stored at -80°C and plaque material is routinely used for standardized (immuno)histochemical analysis^{95,96}. The number of macrophages (CD68), SMAs (α -SMA), intraplaque vessel density (CD34), intraplaque hemorrhage, intraplaque fat, calcification, collagen and plaque vulnerability⁹⁷ were scored as previously described⁹⁸. Genotype data were used to perform regression analyses of histological plaque vulnerability and morphology characteristics, adjusted for age, sex and principal components. Detailed methods are provided in Supplementary Note and scripts are provided at https://github.com/CirculatoryHealth/CHARGE_1000G_CAC.

Heritability estimation of CAC

We used LD-score regression⁴⁷ to estimate the proportion of variance in CAC that could be explained by the aggregated effect of the SNPs in those of European ancestry. The method assumes that an estimated SNP effect includes effects of all SNPs in LD with that SNP. On average, an SNP that tags many other SNPs will have a higher probability of tagging a causal variant than an SNP that tags few other SNPs. Thus, SNPs with a higher LD score have, on average, stronger effect sizes than SNPs with lower LD scores. By regressing the effect size obtained from the GWAS against the LD score for each SNP, the slope of the regression line will provide an estimate of heritability based on the analyzed SNPs. We included 1,167,424 SNPs with available betas. After merging with the European reference panel, 1,164,129 SNPs remained. SNP heritability was estimated using European LD scores from 1000G phase 3 data for the HapMap3 SNPs, downloaded from <https://data.broadinstitute.org/alkesgroup/>.

Genetic correlations

We used cross-trait LD-score regression to estimate the genetic covariation between traits using GWAS summary statistics⁹⁹. The genetic covariance is estimated using the slope from the regression of the product of *z* scores from two GWAS studies on the LD score. The estimate obtained from this method represents the genetic correlation between the two traits based on all polygenic effects captured by SNPs. Standard LD scores were used as provided by Bulik-Sullivan et al. based on the 1000 Genomes reference set¹⁰⁰, restricted to European ancestry populations. Genetic correlations and specific sources of the GWAS studies are provided in Supplementary Table 15.

MR analyses

Two-sample MR using summary-level data was applied to investigate potential causality between CVD risk factors and a higher CAC quantity¹⁰¹ and a higher CAC quantity with CAD. We selected SNPs associated with each CVD risk factor at the genome-wide level of significance ($P < 5 \times 10^{-8}$) as our exposure. SNPs were identified from publicly available GWAS, and only studies with European ancestry populations were considered. We excluded SNPs that had LD with other variants, were

absent from the LD reference panel or were palindromic with intermediate allele frequencies. A total of 75 independent genetic instruments for LDL cholesterol, 83 for HDL cholesterol¹⁰², 54 for triglycerides¹⁰², 375 for systolic blood pressure¹⁰³, 378 for diastolic blood pressure¹⁰³, 74 for BMI¹⁰⁴ and 108 for type 2 diabetes were included. As an outcome, the European ancestry summary statistics of our CAC GWAS were used. Significance was defined as $P < 0.05/7 = 7.14 \times 10^{-3}$ after adjusting for multiple tests. For the association of CAC with CAD, we selected the lead 16 independent SNPs in 11 different loci associated with CAC quantity in the current European GWAS as the exposure and summary statistics of CAD as our outcome⁵⁰. If a requested SNP was not present in the CAD GWAS or identified as palindromic with intermediate allele frequencies, a proxy SNP that was in LD from the European reference panel with the requested SNP was used instead, via the LDproxy Tool from LDlink¹⁰⁵. Alternatively, we selected the five CAC lead SNPs at loci that are not associated with CAD to repeat the MR analysis. IVW analyses were used in which combined effects of the individual genetic instruments on the outcome, here being CAC quantity, result in a weighted mean estimate of a genetically determined increase in exposure on the outcome¹⁰⁶. Moreover, we performed weighted median estimator and MR-Egger regression analyses as sensitivity analyses to rule out potential bias caused by directional pleiotropy¹⁰⁷. The analyses and data visualizations were performed using MRCIEU/TwoSampleMR (v0.5.6)¹⁰⁸ and ggplot2 R packages.

Immunofluorescence analysis in coronary arteries

Freshly isolated coronary arteries were obtained from consented heart transplant recipients or heart donors as described^{39,109}. Briefly, hearts were arrested in cardioplegic solution, transferred on ice and left anterior descending, left circumflex artery and right coronary arteries were dissected from the epicardium, and surrounding adipose and myocardial tissue was carefully removed. Coronary artery segments were grossly scored for presence of lesions, embedded in OCT, snap frozen in liquid nitrogen and stored at -80°C until analysis. OCT blocks were cryosectioned at $8\text{ }\mu\text{m}$. Frozen sections were washed, fixed in 4% formaldehyde, permeabilized with Triton X-100 at 0.05%, blocked with donkey serum and incubated overnight with primary antibodies as follows: mouse anti-ENPP1 (SC-166649, Santa Cruz Biotechnology), rabbit anti-IGFBP3 (10189-2-AP, Proteintech), rabbit anti-ARID5B (HPA015037, Atlas Antibodies) or mouse anti-ADK (SC-514588, Santa Cruz Biotechnology) at 1:100 dilution and mouse anti- α -SMA (SC-53142, Santa Cruz Biotechnology) at 1:100 dilution. Slides were washed with PBS-Tween and incubated with appropriate secondary antibodies. More detailed methods are included in Supplementary Note.

Calcification assay

Calcification was induced in siRNA-transfected cells (20 nM) after 24 h, using osteogenic conditions as described above. Media was changed every 48–72 h, and cells were retreated with siRNA 5 d after initial transfection, again at 20 nM final concentration. Cells were grown in osteogenic conditions for a total of 18 d, after which they were fixed with 4% paraformaldehyde and stained with Alizarin Red to detect calcification. For Alizarin Red staining, cells were incubated with 1% Alizarin Red solution (pH 4.1–4.3) for 10 min, washed multiple times with distilled water and then images were captured.

Proliferation assay

HCASMCs were plated in a 96-well format and treated with either siCTRL, siENPP1, siIGFBP3, siARID5B or siADK at 20 nM final concentration for 24 h. Media was then changed, and cells were incubated for an additional 48 h, at which time MTT assay (30-1010K, ATCC) was performed according to manufacturer instructions. Briefly, MTT reagent was added to each well, and the plate was incubated at 37°C in the dark for 2 h, at which point a purple precipitate was visible inside the cells via light microscopy. Detergent reagent was then added to each well,

and the plate was incubated at room temperature in the dark for an additional 2 h before measurement of absorbance at 570 and 650 nm.

Migration assay

HCASMCs were plated in a 6-well format and treated with either siCTRL, siENPP1, siIGFBP3, siARID5B or siADK at 20 nM final concentration. After 24 h, media was changed, and cells were allowed to incubate for an additional 24 h. Cells were then trypsinized, counted and seeded in silicone insert with a defined cell-free gap (80209, Ibidi) at a density of 4×10^5 cells per ml. Cells were then incubated overnight, dividers were removed, OM was added and cells were observed until sufficient migration had taken place in the control group. After 6 h, all wells were fixed with 4% PFA, stained with Giemsa, and then washed with deionized water. Images were obtained using the Leica DMI 4000B inverted microscopy station and digitized with the Leica Application Suite X software. ImageJ was used to calculate the percentage of the cell-free gap occupied by cells.

Druggability analysis

We used several databases to explore the potential druggability of CAC candidate gene targets prioritized using the various statistical and functional fine-mapping methods. Candidate genes were first annotated for predicted function using the Kyoto Encyclopedia of Genes and Genomes database. We then queried gene targets in the druggable genome using the most recent druggable genome list established by the NIH Illuminating the Druggable Genome Project (<https://github.com/druggablegenome/IDGTTargets>) that are also available via the Pharos web platform. Druggability target categories and predicted drug–gene interactions were queried using an API script for the latest DGIdb (v4.0) to retrieve the top interacting drugs from 43 databases. We also queried protein targets for available active ligands in ChEMBL. We performed a more comprehensive druggability analysis for the identified approved drugs by querying the DrugBank, ChEMBL and ClinicalTrials.gov databases to provide drug annotations, and information on late-stage clinical trials, and disease indications.

Statistical analysis

Details on the statistical tests performed are listed in the respective Methods sections or figure legends. For the functional experiments in cultured SMCs, statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software). Comparisons of more than two groups were performed using a two-tailed one-way ANOVA with Sidak's post hoc correction for multiple comparisons. Data are reported as mean $\pm$ s.e.m., unless otherwise specified. A P value ≤ 0.05 (adjusted for multiple comparisons) was considered statistically significant.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The GWAS meta-analysis summary statistics are available on the EMBL-EBI GWAS catalog (accession numbers: GCST90278455 for the combined data and GCST90278456 for the European-only data) and the Downloads page of the Cardiovascular Disease Knowledge Portal (CVDKP) and will be integrated into CVDKP. Locus zoom plots are available at <https://my.locuszoom.org/gwas/125033/> and FUMA output results are available through the FUMA website. STARNET eQTL data are available in the Database for Genotypes and Phenotypes (dbGaP) via accession: phs001203.v1.p1, as well as web browser: <http://starnet.mssm.edu>. Coronary artery snATAC data are available in the Gene Expression Omnibus database via accession: GSE175621. Athero-Express scRNAseq data are available at <https://doi.org/10.34894/TYHGEF>. snATAC and scRNAseq processed datasets are also available on the PlaqView web portal. Athero-Express GWAS,

and phenotype data are available at <https://doi.org/10.34894/4IKE3T>. Genetic variants for imputation were obtained from 1000 Genomes Phase 3 (v5). Variant annotations were obtained from Ensembl (v92). PheWAS data were obtained from the GWAS Atlas. Gene annotations were obtained from GENCODE (v30). eQTL data were also obtained from Genotype Tissue Expression (GTEx v8). Epigenomics data were obtained from Roadmap Epigenomics (release 9) and ENCODE (v4). Pathway annotations were obtained from MsigDB (v6.2) and Kyoto Encyclopedia of Genes and Genomes (KEGG2). Druggability annotations were obtained from DGIDb (v4.0), IDGTargets, Pharos, ChEMBL, DrugBank and ClinicalTrials.gov. Source data are provided with this paper.

Code availability

General post-GWAS analysis scripts are available at https://github.com/CirculatoryHealth/CHARGE_1000G_CAC. Post-GWAS fine-mapping scripts are available at <https://github.com/MillerLab-CPHG/Fine-mapping/>. Coronary artery snATAC is available at https://github.com/MillerLab-CPHG/Coronary_scATAC.

References

88. Mägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639–3650 (2017).
89. Winkler, T. W. et al. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. *Bioinformatics* **31**, 259–261 (2015).
90. Randall, J. C. et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. *PLoS Genet.* **9**, e1003500 (2013).
91. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
92. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl Acad. Sci. USA* **100**, 9440–9445 (2003).
93. Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. *Nat. Genet.* **53**, 403–411 (2021).
94. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* **44**, W90–W97 (2016).
95. Verhoeven, B. A. N. et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. *Eur. J. Epidemiol.* **19**, 1127–1133 (2004).
96. Van Lammeren, G. W. et al. Atherosclerotic plaque vulnerability as an explanation for the increased risk of stroke in elderly undergoing carotid artery stenting. *Stroke* **42**, 2550–2555 (2011).
97. Verhoeven, B. et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. *J. Vasc. Surg.* **42**, 1075–1081 (2005).
98. Hellings, W. E. et al. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. *J. Vasc. Surg.* **46**, 1147–1154 (2007).
99. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
100. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
101. Lawlor, D. A. Commentary: two-sample Mendelian randomization: opportunities and challenges. *Int. J. Epidemiol.* **45**, 908–915 (2016).
102. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283 (2013).
103. Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat. Genet.* **50**, 1412–1425 (2018).
104. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700,000 individuals of European ancestry. *Hum. Mol. Genet.* **27**, 3641–3649 (2018).
105. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* **31**, 3555–3557 (2015).
106. Bowden, J. & Holmes, M. V. Meta-analysis and Mendelian randomization: a review. *Res. Synth. Methods* **10**, 486–496 (2019).
107. Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur. J. Epidemiol.* **32**, 377–389 (2017).
108. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e005349 (2018).
109. Hartia, J. A. et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. *Eur. Heart J.* **42**, 919–933 (2021).

Acknowledgements

This work was supported by grants from the National Institutes of Health (R01HL148239 and R01HL164577 to C.L.M.; R01HL142809 and R01HL159514 to R.M.; F31HL156463 to D.W.; R01HL125863 to J.L.M.B.; R01HL146860 to P.S.d.V., K01HL164687 to C.L.L.C., N.R.H., P.A.P. and L.F.B.; R01HL163972 to N.F.; P30DK063491 to J.I.R.; R01DK114183 to T.L.A.; European Union funded H2020 TO_AITION (grant 848146 to S.W.v.d.L.); Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation (CVON 2011/B019 and CVON 2017-20 (to S.W.v.d.L. and M.d.W.)—generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS I&II)), the ERA-CVD program ‘druggable-MI-targets’ (01KL1802 to S.W.v.d.L.) and the Leducq Foundation (‘PlaQOmics’ 18CVD02 to C.L.M., J.L.M.B., G.P. and S.W.v.d.L.). The CHARGE Consortium was supported by NHLBI (grant R01HL105756). M.d.W. was supported by the Netherlands Heart Foundation and Spark-Holding BV (2019B016); Leducq Foundation (LEAN 16CVD01); Amsterdam UMC; ZonMW (Open Competition 09120011910025). A full list of the funding support for each study is provided in Supplementary Note. A full list of acknowledged funding support for individual studies is provided in Supplementary Table 23.

Author contributions

C.L.M., D.M.B., J.E.H., J.I.R., L.C.B., L.J.L., M.J.B., M.K., M.M.B., P.A.P., R.M., S.W.v.d.L. and V.G. were responsible for study concept and design. A.G.U., A.T.H., B.G.K., C.L.M., D.B., D.M.B., J.I.R., J.v.d.G., J.v.M., K.D.T., L.-P.L., L.C.B., L.F.B., L.S., M.J.B., M.M., M.W.V., P.A.P., Q.W., R.S., R.Z., S.L.R.K., S.W.v.d.L., T.L.A., V.G. and X.G. were responsible for phenotype data acquisition and/or QC. A.W.T., B.G.K., C.J.H., C.L.L.C., C.L.M., D.B., D.M.B., H.J.B., H.S., J.A.S., J.I.R., K.D.T., L.C.B., L.F.B., M.B., M.J.B., M.M., M.W.V., N.R.Z., P.A.P., S.L.R.K., S.W.v.d.L. and V.G. were responsible for data acquisition. A.T.H., A.V.S., C.J.H., C.L.M., D.W., E.H., H.J.B., H.L., J.D., K.A.Y., L.-P.L., L.F.B., L.P.L.L., L.R.Y., L.S., M.K., M.M., M.M.B., P.A.P., Q.W., S.C., S.M.L., S.W.v.d.L., T.L.A. and X.G. were responsible for statistical analysis and data interpretation. C.L.L.C., C.J.H., C.L.M., D.W., H.J.B., H.L., L.P.L.L., M.K., M.M.B., P.A.P. and S.W.v.d.L. were responsible for drafting the paper. A.G.U., A.T.H., A.V.S., A.W.T., B.G.K., B.M.P., C.J.H., C.J.O., C.L.L.C., C.L.M., D.B., D.M.B., D.W., E.D.B., E.H., H.J.B., H.L., H.M.d.R., H.S., J.A.S., J.C.B., J.C.K., J.D., J.E.H., J.I.R., J.L.M.B., J.v.d.G., J.v.M., J.v.S., K.A.Y., K.D.T., L.-P.L., L.A.L., L.C.B., L.F.B., L.J.L., L.P.L.L.,

L.R.Y., M.A.I., M.B., M.J.B., M.K., M. Kho, M.M.B., M.W.V., N.F., N.R.H., N.R.Z., P.A.P., P.E.S., P.S.d.V., Q.W., R.M., R.S., R.Z., S.C., S.L.R.K., S.M., S.M.L., S.W.v.d.L., T.L.A., V.G., W.S.P. and X.G. were responsible for critical revision of the paper. B.G.K., C.L.M., D.M.B., D.P.v.d.K., G.P., H.M.d.R., H.S., J.I.R., L.A.L., L.C.B., L.J.L., M.d.W., M.J.B., M.K., N.F., N.R.H., P.A.P., P.E.S., P.S.d.V., R.M., R.S., S.L.R.K., S.M., S.W.v.d.L. and V.G. were responsible for funding support. A.D.H., A.W.T., B.I.F., C.D.L., C.F., C.J.O., D.R.J., D.W.B., F.A.A.M.H., I.I., J.C.K., J.G.T., J.J.C., J.L.M.B., J.v.S., J.X., L.A.C., M.A.S., M.F., M.K., M.F.F., O.T.R., R.V., S.-J.H., S.C. and T.L. were responsible for additional resources and/or materials.

Competing interests

S.W.v.d.L. has received Roche funding for unrelated work. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. R.M. receives research funding from Anega Biotherapeutics and Amgen and serves as a consultant for Myokardia/BMS, Renovacor, Epizon Pharma and Third Pole, all unrelated to the current project. C.L.M. has received funding from AstraZeneca on an unrelated project. J.C.K. is the recipient of an

Agilent Thought Leader Award (January 2022), which includes funding for research that is unrelated to the current paper. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41588-023-01518-4>.

Correspondence and requests for materials should be addressed to Maryam Kavousi or Clint L. Miller.

Peer review information *Nature Genetics* thanks Guillaume Lettre, Alexandre Stewart and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at www.nature.com/reprints.